Barcelona

• A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a so … Recruiting
  2024-517419-62-00 4 2025-02-28 HER2 mutation
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• Effect of pharmacological treatment with angiotensin receptor/neprilysin inhibitors on transthyretin cardiac amyloidosis and heart failure w … Recruiting
  2024-515661-34-00 6 2025-02-27 Transthyretin cardiac amyloidosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• A Clinical Trial for Patients with Advanced Cancers Recruiting
  2024-515020-36-00 9 2025-02-24 Advanced Solid tumour
• A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma Recruiting
  2024-515316-44-00 3 2025-02-24 Multiple Myeloma
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1 Recruiting
  2023-509748-89-00 7 2025-02-19 Facioscapulohumeral muscular dystrophy (FSHD)
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 Patients with localised prostate cancer and high-risk features of rela
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• Prospective Randomized Evaluation of Emerging Novel Treatments for Infection prophylaxis in Total Joint Replacement (PREVENT-iT) Recruiting
  2024-515055-38-00 5 2025-02-13 Adult patients undergoing TJR surgery.
• Molecular signatures associated with response to ICS treatment in patients with COPD stratified by eosinophil levels Recruiting
  2023-505245-13-00 6 2025-02-12 Chronic obstructive pulmonary disease (COPD)
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without ext … Recruiting
  2022-502877-41-01 9 2025-02-10 Pulmonary sarcoidosis with or without extrapulmonary manifestations
• A Phase 2 Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM) Recruiting
  2024-513128-40-00 4 2025-02-06 Multifocal Motor Neuropathy
• A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting
  2024-516440-25-00 1 2025-02-06 KRAS G12D-mutant solid tumors.
• Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer … Recruiting
  2024-512960-75-00 5 2025-02-04 Resectable Non-small cell lung cancer
• A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Recruiting
  2024-513199-16-00 1 2025-02-04 Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Rifampicin at High Dose for Difficult-to-Treat Tuberculosis (RIAlta) study Recruiting
  2024-519983-42-00 4 2025-02-04 TUBERCULOSIS
• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema … Recruiting
  2023-509146-35-00 6 2025-01-30 Systemic Lupus Erythematosus

Showing 1,105–1,128 of 3,391 trials